STERILITY TESTING PROCEDURE OF OPHTHALMIC OCUSERT ACICLOVIR USED FOR TREATING HERPES SIMPLEX VIRUS
Â Objective: The present work focuses on sterility studies of prepared aciclovir ocusert which is so essential for ophthalmic preparations. According to Indian Pharmacopoeia, the sterility test was performed. Ocuserts are sterile preparations which are placed into cul-de-sac or conjunctival sac. Ophthalmic inserts offer many advantages over conventional dosage forms such as increased ocular residence time, possibility of releasing drugs at a slow and constant rate and accurate dosing. Ocuserts are formulated for treating external ocular diseases such as conjuctivitis, corneal ulcer, and keratoconjuctivitis. Ophthalmic preparations contaminated with microorganisms cause corneal damage and finally blindness, especially if the microorganism is Pseudomonas aeruginosa. Ophthalmic preparations should be manufactured in aseptic condition and to be sterilized before packing.
Methods: According to Indian Pharmacopoeia, the official sterility test for ocusert was performed for detecting the presence of microbes. The selected F2 formulation which shows controlled drug release after 24 hrs was selected for the sterility test. The F2 formulation was subjected to ultraviolet radiation for sterilization. The sterilized ocusert and unsterilized ocusert were placed in fluid thioglycollate medium and incubated for 7 days at 20-25oC.
Results: After 7 days of incubation, the sterilized ocusert shows no microbial growth and unsterilized ocusert shows microbial growth. The prepared aciclovir ocuserts were found to be sterile after the completion of official sterility test.
Conclusion: The sterility studies conclude after 7 days of incubation period; there was no appearance of turbidity which indicates the prepared formulation F2 was found to be sterile.
2. Karthika K, Padmapreeth J. Comparative review on conventional and advanced ocular drug delivery formulations. Int J Pharm Pharm Sci Rev 2010;2(4):1-5.
3. Ibrahim HM, Ismail HR, Lila AE. Formulation and optimization of ocular poly-D,L-lactic acid nano drug delivery system of amphotericin-B using box behnken design. Int J Pharm Pharm Sci 2012;4(2):342-59.
4. Andonova V, Zagorchev P, Katsarov P, Kassarova M. Eye drops with nanoparticles as drug delivery systems. Int J Pharm Pharm Sci 2015;7:431-5.
5. Robinson JC. In: Mitra AK, editor. Ophthalmic Drug Delivery Systems. New York: Marcel Dekker; 1993. p. 29-57.
6. Sintze MB, Bernatchez SF, Tabatabay C, Gurny R. Biomaterials in ophthalmic drug delivery. Eur J Pharm Biopharm 1996;42:358-74.
7. Lee VH, Robinson JR. Topical ocular drug delivery: Recent developments and future challenges. J Ocul Pharmacol 1986;2(1):67-108.
8. Anonymous. Indian Pharmacopoeia. Vol. 1-2. New Delhi: The Controller of Publication, Govt. of India, Ministry of Health and Family Welfare; 2007. p. 52-9, 142-3, 565-8, 685-8.
9. Anonymous. The Merck Index. 14th ed. USA: Merck Research Laboratories; 2009. p. 26.
10. Anonymous. The United States Pharmacopoeia, NF 27. 32nd ed., Vol. 1. Rockville, MD, USA: The United States Pharmacopeial Convention; 2009. p. 315, 1427-31.
11. Arora DR, Arora B. Text Book of Microbiology. 3rd ed. New Delhi: CBS Publishers and Distributors; 2008. p. 537-47.
12. Balasubramanian J, Srinatha A, Pandit JK, Nath G. In-vitro microbiological evaluation of polyvinyl alcohol based ocular inserts of ciprofloxacin hydrochloride. Indian J Pharm Sci 2003;68(5):626-30.
13. Bagool MA. Topical ocular drug delivery a review. Indian Drugs 1993;31(10):451-6.
14. Chari SS, Makoid MC, Erikson SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974;64:333-8.
15. Dandagi PM. Development and evaluation of ocular films of cromolyn sodium. Indian J Pharm Sci 2004;66(3):309-12.
16. Nithiyananthan TS, Shankarananth V, Rajasekhar KK, Jyothikrishna K, Mukesh O, Kumar EV, et al. Preparation and evaluation of ciprofloxacin ousters. J Pharm Res 2009;2(9):1496-9.
17. Chandran CS, Shirwalkar A, Kiron SS. Development and evaluation of chitosan containing ciprofloxacin-B CD complex. Int J Pharm Technol Res 2010;2(1):246-52.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.